SCHEMBL2365617

SCHEMBL2365617

CN1CCc2ccc(-c3ccnn3C)cc2CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 2/20 0.45
PDK2 Q15119 2/20 0.45
PDK3 Q15120 2/20 0.45
PDK4 Q16654 2/20 0.45
DRD2 P14416 6/20 0.44
USP30 Q70CQ3 1/20 0.44
PIK3CD O00329 1/20 0.43
PIK3CA P42336 1/20 0.43
PIK3CB P42338 1/20 0.43
PI4KA P42356 1/20 0.43
PIK3CG P48736 1/20 0.43
PI4KB Q9UBF8 1/20 0.43
OTUD7B Q6GQQ9 3/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31164675 0.80 ASIC3 (0.55) PDK1PDK2PDK3PDK4DRD2
SCHEMBL25156695 0.77 CYP11B2 (0.46) PDK1PDK2PDK3PDK4DRD2
SCHEMBL2374388 0.76 PDK1 (0.46) PDK1PDK2PDK3PDK4DRD2
SCHEMBL17809556 0.76 PDK1 (0.57) PDK1PDK2PDK3PDK4DRD2
SCHEMBL31164758 0.74 ESR2 (0.61) PDK1PDK2PDK3PDK4USP30
SCHEMBL7923625 0.74 OTUD7B (0.41) PDK1PDK2PDK3PDK4DRD2
SCHEMBL17806355 0.72 PDK1 (0.53) PDK1PDK2PDK3PDK4DRD2
SCHEMBL8030023 0.71 MAOA (0.50) DRD2HRH3DRD1DRD5DRD3
SCHEMBL1903425 0.71 HTR2A (0.39) DRD2DRD1DRD5DRD3DRD4
SCHEMBL25551409 0.70 PIK3CD (0.49) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2363394-A1 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders Arena Pharmaceuticals, Inc. (US) 2011-09-07 EP disclosed